Diamond Equity Has Negative Outlook for BHST Q3 Earnings

Key Points

• Diamond Equity has revised down BioHarvest Sciences' Q3 2025 earnings per share estimate to ($0.17), significantly lower than the previous forecast of ($0.05).
• The company reported a Q2 earnings miss of ($0.15) EPS, falling short of the consensus estimate of ($0.11).
• Despite the downturn, Craig Hallum initiated coverage on BioHarvest Sciences with a "buy" rating and a target price of $15.00.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Research analysts at Diamond Equity reduced their Q3 2025 EPS estimates for shares of BioHarvest Sciences in a research note issued to investors on Wednesday, August 13th. Diamond Equity analyst H. Diamond now anticipates that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.05). The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.06) EPS and Q2 2026 earnings at ($0.03) EPS.

Separately, Craig Hallum initiated coverage on shares of BioHarvest Sciences in a report on Monday, May 5th. They set a "buy" rating and a $15.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, BioHarvest Sciences currently has a consensus rating of "Buy" and a consensus target price of $13.67.

BioHarvest Sciences Stock Up 2.1%

Shares of NASDAQ BHST traded up $0.19 during trading on Friday, reaching $9.40. 4,053 shares of the company traded hands, compared to its average volume of 15,500. The firm has a 50 day simple moving average of $7.50 and a 200-day simple moving average of $6.53. The stock has a market capitalization of $154.35 million, a PE ratio of -13.43 and a beta of 0.68. BioHarvest Sciences has a 52-week low of $4.66 and a 52-week high of $9.90.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.04). The firm had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. BioHarvest Sciences has set its Q3 2025 guidance at EPS.

Hedge Funds Weigh In On BioHarvest Sciences

Large investors have recently added to or reduced their stakes in the company. Magnus Financial Group LLC lifted its holdings in BioHarvest Sciences by 105.0% during the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock valued at $444,000 after purchasing an additional 36,733 shares in the last quarter. True North Advisors LLC lifted its holdings in BioHarvest Sciences by 7.6% during the first quarter. True North Advisors LLC now owns 44,391 shares of the company's stock valued at $275,000 after purchasing an additional 3,120 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new position in BioHarvest Sciences during the fourth quarter valued at approximately $69,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.